TherapeuticsMD, Inc. (TXMD) Institutional Ownership

Ownership Summary

TherapeuticsMD, Inc. (NASDAQ:TXMD) has 43 institutional investors that have filed 13F reports for the period ending December 2025.

• Their combined ownership stood at 31.1% of outstanding shares in December 2025, up from 28.6% in September 2025.
• Their total shares held in TXMD increased 9.62% from the prior quarter, while the number of investors in TherapeuticsMD increased 4.88% year over year.
• Activity in TXMD broke down as 11 buyers, 10 sellers, and 22 unchanged among 43 total holders.
• Altogether, these fund groups held 3.59Mn shares in TXMD by December 2025, up by 315.5K shares quarter on quarter, and down 68.3K shares year over year.
• Rubric Capital Management LP is the top holder of TherapeuticsMD as of December 31, 2025, with 1.19Mn shares representing 10.3% of outstanding stock.
• The biggest buyers of TherapeuticsMD for the quarter ending December 2025 included Squadron Capital Management LLC (420.42K), VANGUARD CAPITAL MANAGEMENT LLC (353.7K), VANGUARD FIDUCIARY TRUST CO (63.83K), RENAISSANCE TECHNOLOGIES LLC (49.7K), CITADEL ADVISORS LLC (40.07K).
• The largest sellers of TherapeuticsMD for the quarter ending December 2025 were ADAR1 Capital Management, LLC (209.21K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (13.94K), OSAIC HOLDINGS, INC. (9.14K), FMR LLC (8.24K), Tejara Capital Ltd (5.0K).
• Per Business Quant, the top 10 investors in TXMD for the quarter ending December 2025 include Rubric Capital Management LP (1.19Mn), Clearline Capital LP (635.22K), Squadron Capital Management LLC (420.42K), VANGUARD CAPITAL MANAGEMENT LLC (353.7K), Tejara Capital Ltd (345.85K), ADAR1 Capital Management, LLC (209.21K), RENAISSANCE TECHNOLOGIES LLC (146.2K), Morgan Stanley (129.22K), BlackRock, Inc. (115.14K), GEODE CAPITAL MANAGEMENT, LLC (109.82K).